ChAd155-hIi-HBV + MVA-HBV + GSK3528869A

This combination therapeutic vaccine regimen for chronic hepatitis B consists of two viral vector-based vaccines—**ChAd155-hIi-HBV** (a chimpanzee adenovirus vector encoding hepatitis B virus antigens), **MVA-HBV** (a Modified Vaccinia Ankara virus vector encoding HBV antigens)—administered with GSK3528869A, which is an adjuvanted recombinant protein formulation. The approach is designed to restore or boost immune responses against hepatitis B virus, aiming for the immunological control of chronic infection and potentially allowing discontinuation of conventional nucleos(t)ide analogue therapy without viral rebound. It is being developed and trialed primarily for adult patients with chronic hepatitis B who are currently under suppressive antiviral therapy. The regimen uses a **prime-boost** strategy (using viral vectors first, then protein boost) aimed at eliciting robust and sustained anti-HBV immune responses, particularly targeting hepatitis B surface antigen (HBsAg) reduction[1][4][5][7][8][9].

Other names

ChAd-hli-HBV + MVA-HBV + GSK3528869AHBV viral vector and adjuvanted proteins vaccine